Education
About Us
Working with TipRanks
Follow Us
Madrigal Pharmaceuticals Inc (MDGL)
NASDAQ:MDGL
Total Valuation
Madrigal Pharmaceuticals has a market cap or net worth of $7.00B. The enterprise value is $5.96B.
Market Cap$7.00B
Enterprise Value$5.96B
Share Statistics
Madrigal Pharmaceuticals has 22,203,281 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding22,203,281
Owned by Insiders19.56%
Owned by Institutions0.25%
Financial Efficiency
Madrigal Pharmaceuticals’s return on equity (ROE) is -0.62 and return on invested capital (ROIC) is -56.97%.
Return on Equity (ROE)-0.62
Return on Assets (ROA)-0.45
Return on Invested Capital (ROIC)-56.97%
Return on Capital Employed (ROCE)-0.57
Revenue Per Employee341.16K
Profits Per Employee-882.37K
Employee Count528
Asset Turnover0.17
Inventory Turnover0.18
Valuation Ratios
The current PE Ratio of Madrigal Pharmaceuticals is -14.09. Madrigal Pharmaceuticals’s PEG ratio is -1.47.
PE Ratio-14.09
PS Ratio0.00
PB Ratio8.70
Price to Fair Value8.70
Price to FCF-14.36
Price to Operating Cash Flow-14.41
PEG Ratio-1.47
Income Statement
In the last 12 months, Madrigal Pharmaceuticals had revenue of 180.13M and earned -465.89M in profits. Earnings per share was -21.90.
Revenue180.13M
Gross Profit173.90M
Operating Income-497.88M
Pretax Income-465.89M
Net Income-465.89M
EBITDA-450.13M
Earnings Per Share (EPS)-21.90
Cash Flow
In the last 12 months, operating cash flow was -395.31M and capital expenditures -6.11M, giving a free cash flow of -401.41M billion.
Operating Cash Flow-395.31M
Free Cash Flow-401.41M
Free Cash Flow per Share-18.08
Dividends & Yields
Madrigal Pharmaceuticals pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta0.88
52-Week Price Change30.06%
50-Day Moving Average326.63
200-Day Moving Average291.50
Relative Strength Index (RSI)46.80
Average Volume (3m)351.68K
Important Dates
Madrigal Pharmaceuticals upcoming earnings date is Aug 6, 2025, TBA Not Confirmed.
Last Earnings DateMay 1, 2025
Next Earnings DateAug 6, 2025
Ex-Dividend Date―
Financial Position
Madrigal Pharmaceuticals as a current ratio of 6.10, with Debt / Equity ratio of 16.85%
Current Ratio6.10
Quick Ratio5.90
Debt to Market Cap0.02
Net Debt to EBITDA-0.04
Interest Coverage Ratio-33.94
Taxes
In the past 12 months, Madrigal Pharmaceuticals has paid 0.00 in taxes.
Income Tax0.00
Effective Tax Rate0.00
Enterprise Valuation
Madrigal Pharmaceuticals EV to EBITDA ratio is -14.63, with an EV/FCF ratio of -14.41.
EV to Sales36.55
EV to EBITDA-14.63
EV to Free Cash Flow-14.41
EV to Operating Cash Flow-14.45
Balance Sheet
Madrigal Pharmaceuticals has $843.07M in cash and marketable securities with $119.77M in debt, giving a net cash position of -$723.30M billion.
Cash & Marketable Securities$843.07M
Total Debt$119.77M
Net Cash-$723.30M
Net Cash Per Share-$32.58
Tangible Book Value Per Share$35.24
Margins
Gross margin is 96.67%, with operating margin of -276.39%, and net profit margin of -258.64%.
Gross Margin96.67%
Operating Margin-276.39%
Pretax Margin-258.64%
Net Profit Margin-258.64%
EBITDA Margin-249.88%
EBIT Margin-250.49%
Analyst Forecast
The average price target for Madrigal Pharmaceuticals is $424.21, which is 11.43% higher than the current price. The consensus rating is Strong Buy
Price Target$424.21
Price Target Upside38.46% Upside
Analyst ConsensusStrong Buy
Analyst Count15
Revenue Growth Forecast―
EPS Growth Forecast21.83%